Therapies for psoriatic enthesopathy. A systematic review

Journal of Rheumatology

Volumn 33, Issue 7, 2006, Pages 1435-1438

  Ritchlin, Christopher T ^a,b,c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Department of Medicine ^*  (United States)

^c Clinical Immunology Research Unit   (United States)

Author keywords

Ankylosing spondylitis; Enthesitis; Enthesopathy; Psoriatic arthritis; Spondyloarthropathy; Treatment

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; MESALAZINE; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACHILLES TENDINITIS; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; CLINICAL TRIAL; COCHRANE LIBRARY; DISEASE SEVERITY; ECHOGRAPHY; ENTHESITIS; ENTHESOPATHY; EPICONDYLITIS; EVIDENCE BASED MEDICINE; HUMAN; MAASTRICHT ANKYLOSING SPONDYLITIS ENTHESITIS SCORE; MANDER ENTHESITIS INDEX; MEDLINE; META ANALYSIS; MONOCYTE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHYSIOTHERAPY; PLANTAR FASCIITIS; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; EVIDENCE-BASED MEDICINE; HUMANS; JOINTS; PHYSICAL THERAPY MODALITIES; RANDOMIZED CONTROLLED TRIALS; RHEUMATIC DISEASES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33745804708     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis 1973;32:181-201.
2. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64 Suppl 2:ii49-54.
3. Laloux L, Voisin MC, Allain J, et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2001;60:316-21.
4. McGonagle D, Marzo-Ortega H, O'Connor P, et al. Histological assessment of the early enthesitis lesion in spondyloarthropathy. Ann Rheum Dis 2002;61:534-7.
5. McGonagle D, Gibbon W, O'Connor P, Green M, Pease C, Emery P. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy [comment]. Arthritis Rheum 1998;41:694-700.
6. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study [comment]. Arthritis Rheum 2001;44:2112-7.
7. Mander M, Simpson JM, McLellan A, Walker D, Goodacre JA, Dick WC. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987;46:197-202.
8. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2004-12.
9. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127-32.
10. Gladman DD, Cook RJ, Schentag C, et al. The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the Spondyloarthritis Research Consortium of Canada. J Rheumatol 2004;31:1126-31.
11. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005;52:1227-36.
12. Antoni CE, Krueger G, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 Trial. Ann Rheum Dis 2005;64:1150-7.
13. Kane D. The role of ultrasound in the diagnosis and management of psoriatic arthritis. Curr Rheumatol Rep 2005;7:319-24.
14. D'Agostino MA, Said-Nahal R, Breban M. Assessment of peripheral enthesitis in spondyloarthropathies by ultrasonography combined with power doppler: a cross-sectional study. Arthritis Rheum 2003;48:523-33.
15. Grigoryan M, Roemer FW, Mohr A, Genant HK. Imaging in spondyloarthropathies. Curr Rheumatol Rep 2004;6:102-9.
16. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 1996;39:2013-20.
17. Lehtinen A, Leirisalo-Repo M, Taavitsainen M. Persistence of enthesopathic changes in patients with spondylarthropathy during a 6-month follow-up. Clin Exp Rheumatol 1995;13:733-6.
18. Thomson GT, Thomson BR, Thomson KS, Ducharme JS. Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies. J Rheumatol 2000;27:714-8.
19. Altan L, Bingol U, Karakoc Y, Aydiner S, Yurtkuran M. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 2001;30:255-9.
20. Erratum in: Scand J Rheumatol 2003;32:380 .
21. Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36.
22. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha [see comment]. N Engl J Med 2002:1349-56.
23. Felson DT, McLaughlin S, Goggins J, et al. Bone marrow edema and its relation to progression of knee osteoarthritis. Ann Intern Med 2003;139 (Pt 1):330-6.
24. McGonagle D, Marzo-Ortega H, O'Connor P, et al. The role of biomechanical factors and HLA-B27 in magnetic resonance imaging-determined bone changes in plantar fascia enthesopathy. Arthritis Rheum 2002;46:489-93.